- Home
- MPT vs SLS Comparison
MPT vs SLS Comparison
Compare MPT & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MPT | SLS |
|---|---|---|
| Founded | 2003 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.7B |
| IPO Year | 2004 | 2007 |
Fundamental Metrics
Financial Performance| Metric | MPT | SLS |
|---|---|---|
| Price | $3.54 | $11.52 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $5.00 | ★ $10.00 |
| AVG Volume (30 Days) | ★ 9.8M | 5.5M |
| Earning Date | 04-30-2026 | 05-11-2026 |
| Dividend Yield | ★ 6.43% | N/A |
| EPS Growth | ★ 88.56 | 50.00 |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $972,022,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.91 | $110.98 |
| P/E Ratio | $70.00 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.36 | $1.39 |
| 52 Week High | $6.47 | $15.88 |
Technical Indicators
Market Signals| Indicator | MPT | SLS |
|---|---|---|
| Relative Strength Index (RSI) | 38.66 | 43.39 |
| Support Level | $3.36 | $10.82 |
| Resistance Level | $5.32 | $15.77 |
| Average True Range (ATR) | 0.13 | 0.83 |
| MACD | 0.02 | -0.09 |
| Stochastic Oscillator | 40.45 | 24.18 |
Price Performance
Historical ComparisonAbout MPT Medical Properties Trust Inc. common stock
Medical Properties Trust Inc acquires and develops net-leased healthcare facilities. Its investments in healthcare real estate, other loans, and any investments in tenants are considered a single reportable segment. Its business strategy is to acquire and develop healthcare facilities and lease the facilities to healthcare operating companies under long-term net leases, which require the tenant to bear of the costs associated with the property. The group's geographic areas are the United States, the United Kingdom, and All other countries.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.